HeartBeam Inc. (NASDAQ: BEAT), a medical technology company specializing in advanced electrocardiogram (ECG) solutions, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's "Total Cardiac Intelligence" report. The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. This recognition underscores HeartBeam’s growing influence in the next generation of cardiac monitoring technology.
According to the article highlighting this achievement, HeartBeam's ranking reflects the rapid maturation of its proprietary synthesis-ECG system. This system captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. The unique approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings. By doing so, HeartBeam is addressing one of modern medicine’s most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. The company is currently cleared for arrhythmia detection, with ischemia monitoring as a future goal.
HeartBeam is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed for use in portable devices that can be deployed wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care—all outside a medical facility, redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com.
The recognition from PatentVest highlights HeartBeam's intellectual property strength and innovation in a competitive field. The analysis included 243 firms, with HeartBeam ranking second, indicating a significant leap in its technological capabilities. The company's synthesis-ECG system represents a departure from traditional 12-lead ECGs, which require multiple cables and a clinical setting. By miniaturizing and simplifying the process, HeartBeam aims to expand access to cardiac monitoring, potentially reducing time to diagnosis and improving outcomes for patients with arrhythmias and, eventually, ischemia.
HeartBeam's achievement is particularly notable given the dominance of large players like GE Healthcare in the ECG market. The ranking suggests that HeartBeam's innovative approach has the potential to disrupt the status quo, offering a more portable and patient-friendly solution. As the company continues to develop its technology, it may pave the way for broader adoption of remote cardiac monitoring, which has become increasingly important in an era of value-based care and telehealth expansion. For the latest news and updates relating to BEAT, visit the company’s newsroom at https://ibn.fm/BEAT.
